LX2006 Shows Statistically Significant Efficacy, Pivotal Trial Advances for Lexeo Therapeutics
LXEO has more than doubled off its 52-week low of $1.45.
Summary
Lexeo Therapeutics reported strong operational highlights alongside its Q4 and full-year 2025 financial results. The company announced statistically significant improvement in mean mFARS scores for its lead program, LX2006, in Friedreich Ataxia, with continued encouraging efficacy and safety data. The protocol for the pivotal SUNRISE-FA 2 trial for LX2006 has been submitted to the FDA, with study initiation on track for the first half of 2026, significantly de-risking the program. Additionally, Lexeo established a research collaboration with Johnson & Johnson and reported a robust cash position of $246.6 million, providing an operational runway into 2028. Investors will be watching for FDA feedback on the pivotal trial protocol in Q2 2026 and the commencement of the SUNRISE-FA 2 trial.
At the time of this announcement, LXEO was trading at $5.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $384.6M. The 52-week trading range was $1.45 to $10.99. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.